GIUGLIANO, FEDERICA
GIUGLIANO, FEDERICA
Universita' degli Studi di MILANO
Baseline Tumor Size as Prognostic Index in Patients With Advanced Solid Tumors Receiving Experimental Targeted Agents
2023 E. Nicolò, P. Tarantino, O. D'Ecclesiis, G. Antonarelli, L. Boscolo Bielo, A. Marra, S. Gandini, E. Crimini, F. Giugliano, P. Zagami, C. Corti, D. Trapani, S. Morganti, C. Criscitiello, M. Locatelli, C. Belli, A. Esposito, I. Minchella, M. Cristofanilli, S.M. Tolaney, G. Curigliano
Unlocking the Resistance to Anti-HER2 Treatments in Breast Cancer: The Issue of HER2 Spatial Distribution
2023 F. Giugliano, A. Carnevale Schianca, C. Corti, M. Ivanova, N. Bianco, S. Dellapasqua, C. Criscitiello, N. Fusco, G. Curigliano, E. Munzone
Breast Cancer with Brain Metastasis: Molecular Insights and Clinical Management
2023 M. Ivanova, F.M. Porta, F. Giugliano, C. Frascarelli, E. Sajjadi, K. Venetis, G. Cursano, G. Mazzarol, E. GUERINI ROCCO, G. Curigliano, C. Criscitiello, N. Fusco
HER2-Low Breast Cancer: a New Subtype?
2023 C. Corti, F. Giugliano, E. Nicolò, P. Tarantino, C. Criscitiello, G. Curigliano
A set of easy and stringent criteria to identify immune-related adverse events (IrAE Scoring System, ISS) improves correlation with outcome in a phase 1-2 trial population
2022 L. Mazzarella, F. Giugliano, E. Nicolo', E. Crimini, J. Uliano, C. Corti, P. D'Amico, P. Aliaga, C. Valenza, M. Repetto, G. Antonarelli, L. Ascione, G. Vivanet, P. Giachetti, I. Minchella, C. Belli, A. Esposito, M. Locatelli, C. Criscitiello, G. Curigliano
Evolution of low HER2 expression between early and advanced-stage breast cancer
2022 P. Tarantino, S. Gandini, E. Nicolo, P. Trillo, F. Giugliano, P. Zagami, G. Vivanet, F. Bellerba, D. Trapani, A. Marra, A. Esposito, C. Criscitiello, G. Viale, G. Curigliano
Harmonizing PD-L1 testing in metastatic triple negative breast cancer
2022 F. Giugliano, G. Antonarelli, P. Tarantino, J. Cortes, H.S. Rugo, G. Curigliano
SARS-CoV-2 vaccine in patients with thymic epithelial tumours with and without active or pre-existing autoimmune disorders: Brief report of a TYME network safety analysis
2022 F. Giugliano, P.A. Zucali, G. Galli, Z. Ballatore, C. Corti, P.T. Aliaga, J. Uliano, G. Vivanet, G. Curigliano, F. Conforti, P. Queirolo, R. Berardi, S. Manglaviti, G. Apollonio, M. Perrino, F. Borea, F. D'Antonio, M.C. Garassino, T. De Pas
Bystander effect of antibody-drug conjugates: fact or fiction?
2022 F. Giugliano, C. Corti, P. Tarantino, F. Michelini, G. Curigliano
Combining antibody-drug conjugates with immunotherapy in solid tumors: current landscape and future perspectives
2022 E. Nicolò, F. Giugliano, L. Ascione, P. Tarantino, C. Corti, S.M. Tolaney, M. Cristofanilli, G. Curigliano
Baseline tumor size as prognostic index in patients with cancer receiving experimental targeted agents
2022 P. Tarantino, O. D'Ecclesiis, E. Nicolò, G. Antonarelli, L. Boscolo Bielo, A. Marra, S. Gandini, E. Crimini, F. Giugliano, P. Zagami, C. Corti, D. Trapani, S. Morganti, C. Criscitiello, M.A. Locatelli, C. Belli, A. Esposito, I. Minchella, S.M. Tolaney, G. Curigliano
Auto-immune toxiity of Sars-Cov2 vaccine in patients with thymic epithelial tumours: a prospective analysis from the tyme net
2021 F. Giugliano, C. Corti, F. Conforti, P. Queirolo, E. Pennacchioli, C. Catania, L. Pala, G. Curigliano, T. De Pas
Characterization of low HER2 expressions in de-novo metastatic breast cancer
2021 P. Tarantino, E. Nicolo, P. Zagami, F. Giugliano, P. Aliaga, E. Crimini, C. Corti, J. Uliano, S. Morganti, L. Mazzarella, C. Criscitiello, A. Esposito, G. Curigliano
Antibody–drug conjugates for the treatment of breast cancer
2021 C. Corti, F. Giugliano, E. Nicolo, L. Ascione, G. Curigliano
Immune-related adverse events are correlated with significantly improved outcome in a phase I trial population exposed to combination immunotherapy
2021 L. Mazzarella, F. Giugliano, E. Crimini, J. Uliano, C. Corti, P. D'Amico, P. Aliaga, C. Valenza, M. Repetto, E. Nicolo, G. Antonarelli, L. Ascione, G. Vivanet, P. Giachetti, C. Belli, C. Criscitiello, A. Esposito, M. Locatelli, I. Minchella, G. Curigliano
Research and clinical landscape of bispecific antibodies for the treatment of solid malignancies
2021 G. Antonarelli, F. Giugliano, C. Corti, M. Repetto, P. Tarantino, G. Curigliano
Benefit of adjuvant chemotherapy in patients with special histology subtypes of triple-negative breast cancer : a systematic review
2021 D. Trapani, F. Giugliano, J. Uliano, V.A.A. Zia, A. Marra, G. Viale, E. Ferraro, A. Esposito, C. Criscitiello, P. D'Amico, G. Curigliano
Selective FGFR/FGF pathway inhibitors: inhibition strategies, clinical activities, resistance mutations, and future directions
2021 M. Repetto, E. Crimini, F. Giugliano, S. Morganti, C. Belli, G. Curigliano
First line treatment of BRAF mutated advanced melanoma: Does one size fit all?
2021 F. Giugliano, E. Crimini, P. Tarantino, P. Zagami, J. Uliano, C. Corti, D. Trapani, G. Curigliano, P.A. Ascierto
Margetuximab for the treatment of HER2-positive metastatic breast cancer
2021 P. Tarantino, S. Morganti, J. Uliano, F. Giugliano, E. Crimini, G. Curigliano